Integrated research organisation (IRO) Elligo Health Research has raised $20m in a series C funding round led by Piper Jaffray Merchant Banking.
The round was joined by all lead series A and B investors. The company’s $16m series B financing was carried out in March last year.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Elligo Health intends to use the latest funds to further boost physician and patient access to clinical trials using its Goes Direct approach and IntElligo Research Stack clinical technology.
The company is engaged in connecting clinical experts with research infrastructure in order to offer an improved clinical trial solution.
Elligo Health Research CEO John Potthoff said: “The goal is to drive clinical trial efficiency through innovation. Our investors’ continued support in our unique Goes Direct approach and novel IntElligo Research Stack clinical technology has allowed us to quickly expand the base of physicians and their patients who otherwise would not participate in clinical trials.”
Under the Goes Direct approach, the company uses study criteria, including therapeutic specialty and patient pool demographics, to search electronic health records and link medical practices with future trial opportunities.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company provides the practice with the infrastructure, technology and expertise required to perform a trial.
Elligo’s IntElligo Research Stack platform is designed to identify qualified patients at the study site.
If a patient is interested in participating, Elligo’s study coordinator will be responsible for scheduling visits, processing paperwork, as well as handling data collection, regulatory compliance and sponsor communication.
According to the company, the Goes Direct approach also helps trial sponsors and contract research organisations (CROs) by saving time and resources.
